Adagene Inc.
ADAG · XNASCIK 1818838fmd_0RE87K4ZTXPGAEVR6SAZBZWBWSManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Dec 31, 2025, 11 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | 2 | 0 | 1 | 10 | 9 | 18 | 0 | 8 |
| Research and development | 16 | 16 | 34 | 68 | 81 | 37 | 29 | 22 |
| Operating income | (17) | (19) | (43) | (72) | (84) | (24) | (36) | (21) |
| Interest expense | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 |
| Interest and investment income | – | – | – | – | 0 | 4 | 4 | 2 |
| Income before taxes | (15) | (16) | (42) | (17) | (13) | (17) | (33) | (18) |
| Income tax expense | – | – | – | 2 | 0 | 2 | (0) | (0) |
| Net income from continuing operations | – | – | – | (19) | (14) | (19) | (33) | (18) |
| Net income | (15) | (16) | (42) | (73) | (80) | (19) | (33) | (18) |
| Net income to common shareholders | (14) | (17) | (43) | (73) | (80) | (19) | (33) | (18) |